ebook img

Diagnostic Microbiology and Infectious Disease 1994: Vol 18-20 Index PDF

25 Pages·1994·10.6 MB·English
by  
Save to my drive
Quick download
Download
Most books are stored in the elastic cloud where traffic is expensive. For this reason, we have a limit on daily download.

Preview Diagnostic Microbiology and Infectious Disease 1994: Vol 18-20 Index

Author Index to Volumes 18, 19, and 20 Aarnaes, S.L., 19:221 Cohen, M.A., 18:31, 18:41 Gaskins, D., 18:181 Ahluwalia, G.S., 18:161 Cook, R.A., 18:89 Gayowski, T., 19:1 Alami, S.Y., 20:151 Cooksey, R.C., 18:215 Gegundez, M.I., 19:171 Albert, M.J., 18:145, 19:47, 20:209 Cooper, G., 20:1 Gelfand, M., 18:235 Alden, B., 20:13 Courtney, R.R., 19:61 Gerlach, E.H., 18:243 Aldridge, K.E., 18:191, 18:235, 19:227, 20: Crane, L.R., 18:89 Getsinger, L.J., 19:101 135 Crawford, J.T., 18:215 Goldman, M., 20:175 Alfa, M.J., 18:121 Croco, J.L., 20:213 Gomez-Garcés, J.L., 19:69 Al6s, J.-I., 19:69 Cutie, E., 18:95 Gootz, T.D., 19:235 Altaie, $.S., 18:141, 18:175 Grant, C.E., 18:1 Alvarez, M., 18:95 da Gloria Siqueira Carvalho, M., 20:61 Greenaway, C., 18:121 Ampel, N.M., 18:83 Dalton, M.T., 20:1 Grigoriew, G.A., 19:89 Anand, C.M., 18:229 DeAngelis, P.L., 20:77 Anderson, J.D., 18:79 de Araujo Vieiralves, L.F., 19:121 Haase, D., 20:181 Anderson, M.R., 19:235 de la Maza, L.M., 19:221 Halkias, K., 18:181 Anderson, S.C., 19:203 Della Latta, P., 18:13 Hammond, G.W., 18:161 Ansaruzzaman, M., 19:47 Dessens, M., 19:151 Harrell, L.J., 20:121 Appelbaum, P.C., 18:25 Dill, S.R., 18:259 Harrison, L.H., 18:211 Araj, G.F., 20:151 Di Nuzzo, A.R., 20:113 Haskell, S.L., 19:235 Arnold, R.R., 20:69 Dionisio, D., 18:7 Hassett, D.J., 20:187 Axelrod, P., 18:251 DiTomasso, J.P., 18:83 Haugen, T.H., 20:13 Ayers, L.W., 18:235 Doern, G.V., 18:243, 20:109 Hegewald, S., 20:163 Azim, T., 18:145, 19:47 Donabedian, H., 18:111 Heifetz, C.L., 18:31, 18:41 Dryja, D., 18:141, 18:175 Heinzer, I., 20:117 Bacon III, A.E., 18:205 Dulworth, J.K., 18:117 Henderberg, A., 18:235 Baddour, L.M., 19:245 Durkin, M.M., 18:197 Himmelright, I.M., 19:245 Baker, C.N., 19:167 Hindler, J., 18:243 Bale, M.J., 18:151, 19:9, 19:65, 19:75, 19:175 Edinger, R., 19:61 Hoban, D.J., 18:49, 18:167 Balows, A., 19:135, 19:249, 20:119 Eng, R.H.K., 18:105 Hoban, S., 18:121 Ephgrave, K.S., 19:197 Barrett, M.S., 19:93, 19:183 Hohl, P., 19:121 Bartlett, M.S., 18:197 Ephraim, D.A., 18:137 Hollick, G.E., 19:61 Bes, M., 19:25 Erwin, M.E., 18:125, 18:243, 19:65, 19:183, Hollis, R.J., 19:197, 20:127 Biedenbach, D.J., 19:93 19:203, 20:49, 20:93, 20:213 Hoque, S.S., 20:209 Biehle, J.R., 19:101 Espinel-Ingroff, A., 19:9, 19:217, 20:81, 20: Hossain, A., 18:145, 19:47 Bingen, E., 18:263 87 Houston, A.K., 18:57 Bland, S., 19:25 Hsieh, W.-C., 19:143 Blanding, J., 19:221 Fan-Havard, P., 18:105 Huang, M.B., 19:167 Bloom, J.W., 18:83 Fang, K.-M., 18:69 Faruque, A.S.G., g20:209 Huband, M.D., 18:31 Bolmstrém, A., 19:187 Bonfiglio, G., 19:163 Fasola, E.L., 19:57 Huber, M.B., 20:113 Borges, C.E., 19:121 Fekete, T., 18:251 Hubinette, M.M., 20:27 Fekety, R., 18:205 Hunt, J.M., 18:219 Brackman, M.A., 18:117 Brady, S.L., 18:197 Felmlee, T.A., 18:219 Brighty, K.E., 19:235 Finegold, S.M., 19:129 Ieven, M., 18:157 Brookings, E., 18:181 Finlay, J.E., 20:171 In Vitro Susceptibility Surveillance Group, Budd, N., 18:111 Fleurette, J., 19:25 19:111 Fluoroquinolone Resistance Surveillance Bumgardner, R.V., 18:1 Buschelman, B., 19:9, 19:75 Group, 19:203 Jacobs, M.R., 18:25 Fonseca, K., 18:229 Janney, A., 18:235 Forthal, D., 19:221 Cantrell, H.F., 19:111, 20:143 Jenkins, S., 18:181 Forward, K.R., 20:1 Carroll, K., 20:163 Jennings, J.M., 20:213 Fraser, S., 20:195 Castaldi, M.J., 19:235 Jensen, C., 19:137 Frei, R., 18:167 Cavalieri, S.J., 19:101 Jesudason, M.V., 18:75 Freney, J., 19:25 Chang, S.-C., 19:143 Joannides, E.T., 18:31 Friedland, L.R., 20:187 Chapin-Robertson, K., 18:259 John, T.J., 18:75, 18:211 Fuchs, P.C., 18:151 Chee, S.L., 19:89 Fung-Tomc, J.C., 18:129 Johnson, D.M., 18:125 Cherubin, C.E., 20:21 Furness, K., 18:175 Johnson, F.B., 19:137 Chow, A.W., 19:39 Johnson, H.W., 18:79 Chowdhury, A., 18:145 Gadea, I., 19:171 Johnson, M., 18:235 Chua, R., 20:195 Gage, J.W., 18:41 Johnson, W.M., 20:181 Clarke, A.M., 20:27 Galgiani, J.N., 18:89, 20:81 Jones, R.N., 18:49, 18:57, 18:61, 18:125, 18: Cogollos, R., 19:69 Gallimore, B., 19:39 133, 18:151, 18:167, 18:243, 19:33, 19:65, Cohen, M., 18:25 Gallis, H.A., 18:89 19:93, 19:149, 19:175, 19:183, 19:203, 20: Author Index to Volumes 18, 19, and 20 49, 20:93, 20:143, 20:159, 20:167, 20:203, Messer, S.A., 20:127 Raszka, W.V., Jr., 18:201 20:213 Mieles, L., 19:1 Reising, S.F., 20:187 Jorgensen, J.H., 20:41 Mills, K., 19:179 Reller, L.B., 18:235, 20:121 Mirrett, S., 20:121 Rennie, K.A., 20:57 Kabir, I., 19:47 Molitoris, E., 19:129 Restieri, C., 19:39 Moody, J.A., 19:57 Reverdy, M.E., 19:25 Kaka, S., 20:105 Kanga, J.-M., 19:121 Morales, E., 18:95 Rex, J.H., 19:9 Kehrberg, E.N., 19:203 Moreno, F., 20:41 Rhomberg, P.R., 18:151, 19:75, 19:175, 20:159 Morice, N., 19:227 Rihs, J.D., 19:1 Kenny, M.T., 18:117 Morthland, V.H., 19:197 Rinaldi, M.G., 19:9 Kerr, E., 20:1 Kessler, R.E., 18:129 Muder, R.R., 20:99 Rittenhouse, S.F., 20:171 Keystone, J., 19:89 Mukundan, S., 18:75 Robbie, L., 20:109 Khosid, H.E., 20:195 Murmans, M., 19:151 Roberts, G.D., 18:219 Kissling, M., 19:121 Murphy, S.P., 20:49 Rogés, G., 18:95 Kitching, D.A., 20:195 Murray, B.E., 20:45 Roland, G.E., 18:31, 18:41 Kleiman-Wexler, R.L., 19:197 Murray, P.R., 19:111 Root, P.P., 19:19 Klisko, B., 18:161 Rozee, K.R., 20:181 Kluchka, C., 18:229 Naidu, A.S., 20:69 Ruddy, R.M., 20:187 Klugman, K.P., 20:105 Nguyen, M.H., 20:99 Kobayashi, J., 18:19 Nicholson, D., 20:13 Sabria-Leal, M., 19:197 Koontz, F.P., 18:151, 19:183 Nieto, E., 19:171 Sader, H.S., 20:93, 20:203 Korten, V., 20:45 Niubo, J., 19:15 Safran, C., 18:263 Kraatz, J., 20:175 Noble, R.C., 19:51 Salam, M.A., 20:209 Krajden, M., 19:89 North American Ofloxacin Study Group, Saldana, C.J., 20:33 Kreter, B., 18:251 18:49 Salfinger, M., 19:81 Sanchez, M.L., 18:61 Lalitha, M.K., 18:211 O’Donnell, E., 18:111 Sanchez-Portocarrero, J., 20:33 Lancaster, M., 19:9 O’Donovan, C.A., 18:105 Sanders, C.V., 18:235 Lankford, R.B., 19:111, 20:143 Olafsson, J.H., 18:101 Saramago Stern, C., 20:61 Laverdiére, M., 19:39 Olsen, M.A., 19:19 Sartor, V.E., 20:163 Law, L., 19:89 Olszewski, C., 18:111 Satishchandran, V., 18:251 Lee, C.-H., 18:197 Ongsansoy, E., 18:121 Sato, Y., 18:19 Lee, N., 18:69 O’Quinn, K.J., 19:5 Saubolle, M.A., 19:101 Lee, T.-T., 18:69 Otero, A., 18:95 Schiro, D.D., 18:191, 18:235, 19:227, 20:135 Legere, E.A., 20:195 Overman, S.B., 19:51 Schlievert, P.M., 19:245 Lewis, J., 18:181 Schmieder, B.J., 19:235 Schmitz, P.I.M., 19:151 Livermore, D.M., 19:163 Paisley, N., 20:1 Lomefloxacin Study Group, 20:93 Schoenknecht, F., 18:235 Palsdottir, R., 18:101 Scott-Taylor, T.H., 18:161 Low, D.E., 19:5, 20:195 Pappas, P.G., 18:89 Segreti, J., 20:175 Lucena, R., 19:121 Patel, M.P., 19:5 Luh, K.-T., 19:143 Pattyn, S., 18:157 Sesnie, J.C., 18:31 Lungu, O., 18:13 Penate, G., 18:95 Sewell, D.L., 18:1 Lunz, R., 20:105 Pérez, J.L., 19:15 Shanholtzer, C.J., 19:57 Lyons, E., 20:195 Pérez-Cecilia, E., 20:33 Shapiro, M.A., 18:31 Shibl, A.M., 20:7 Perl, T.M., 18:151 Shiroma, Y., 18:19 MacArthur, R.D., 18:111 Persing, D.H., 18:219 Macdonald, N.E., 20:181 Peterson, E.M., 19:221 Sigvaldadé6ttir, E., 18:101 MacLaren, D.M., 19:151 Peterson, L.R., 19:57 Silverstein, S., 18:13 Mailloux, G.B., 18:41 Pfaller, M.A., 18:1, 18:151, 19:9, 19:75, 19: Simonetti, M.T., 18:7 Marco, F., 18:167 197, 20:127, 20:203 Simor, A.E., 19:5, 20:195 Mariscal, D., 19:15 Phillips, A.M., 19:5 Simpson, H.E., 19:5 Marrama, L., 20:109 Pierson, C.L., 18:235 Singh, N., 19:1 Marrero, M., 18:95 Pignatari, A.C., 18:167 Skillman, L.P., 18:201 Marshall, S.A., 19:33 Poonia, K., 19:39 Skulnick, M., 19:5, 20:195 Martin, R., 19:15 Pottage, J.C., Jr., 18:89 Small, G.W., 19:5 Martino, R.L., 18:259 Poupard, J.A., 20:171 Smeets T., 19:151 Prasad, E.S., 20:57 Martin-Rabadan, P., 20:33 Smid, I., 19:81 Privitera, G., 19:157 Martins Teixeira, L., 20:61 Smith, J.W., 18:197 Provinciael, D., 18:157 Mathew, T., 18:121 Smith, R.J., 19:245 Putnam, L.R., 20:213 Matthey, S., 20:13 Smith, S.M., 18:105 Mayer, J., 20:163 Sobonya, R.E., 18:83 McDonald, C.L., 18:259 Qadri, F., 18:145 Soriano, F., 19:171 McEvoy, P.L., 18:201 Quality Control Study Group, 19:65 Souza, I.E., 20:13 McGuirk, P.R., 19:235 Spangler, S.K., 18:25 Meli, M., 18:7 Ramadan, M.A., 20:7 Speier, S.,.19:221 Menon, A.G., 20:187 Rand, K., 18:181 Spitzer, E.D., 18:137 Meservey, M.A., 18:31, 18:41 Rangaraj, M., 18:263 Sridharan, G., 18:75, 18:211 Author Index to Volumes 18, 19, and 20 Steele-Moore, L., 18:175, 20:81, 20:87 Unicomb, L., 19:47 Werkmeister, L., 19:197 Steingrimsson, O., 18:101 Utrup, L.J., 20:171 Wexler, H.M., 19:129 Steinhoff, M.C., 18:211 Uwaydah, M.M., 20:151 Wilkins, J., 18:235 Stobberingh, E.E., 19:151 Williams, J.A., 18:1 Stockman, L., 18:219 Vael, K., 18:157 Wold, S.A., 18:41 Stratton, C.W., 20:21 Valdes, O., 18:95 Woods, G.L., 20:113 Sutcliffe, J.A., 19:235 Van Klingeren, B., 19:151 Woodwell, J., 18:251 Sutton, L.D., 20:143 Van Overmeire, B., 18:157 Van Reempts, P., 18:157 Yamane, N., 18:167 Takara, M., 18:19 Villareal, K.M., 18:89 Yang, J., 19:89 Tawfik, A.-K.F., 20:7 Yangco, B., 18:181 Tecson-Tumang, F.T., 18:105 Waites, K., 18:181 Yoder, S.L., 18:41 Tenover, F.C., 19:167 Walmsley, S., 19:89 Young, S.A., 19:197 Tilton, R.C., 18:235 Wang, J., 18:197 Yu, V.L.,: 3&1 Toma, H., 18:19 Tomayko, J.F., 20:45 Wanger, A., 19:179 Wehrli, M., 20:117 Zabransky, R.J., 20:113 Tortoli, E., 18:7 Trenholme, G.M., 20:175 Weigel, P.H., 20:77 Zambardi, G., 19:25 Trombley, C.L., 18:79 Weiner, M.H., 20:41 Zapardiel, J., 19:171 Truant, A., 18:251 Weitzman, I., 18:13 Zappelini, M., 19:121 Tubau, F., 19:15 Wenman, W.M., 20:57 Zbinden, R., 20:117 Tumah, H., 18:251 Wenzel, R.P., 18:89 Zemcov, S.J.V., 20:27 225 Subject Index to Volumes 18, 19, and 20 Abbott IMx microparticle enzyme immuno- transport media for viability maintenance against Bacteroides fragilis, 18:235-241, 19: assay, for Toxoplasma-specific IgG, of, 19:137-142 227-234 19:19-24 Aeromonas hydrophila against Clostridium spp., 19:227-234 Abdomen cefepime against, 18:170 against Enterococcus faecalis, 18:34 Candida spp. in, 20:33—40 ceftazidime against, 18:170 against Enterococcus faecium, 20:42 Mobiluncus mulieris in, 20:163—165 FK-037 against, 18:170 against Escherichia coli, 18:35 Streptococcus anginosus in, 19:70—73 Aeromonas spp., FK-307 against, 20:27-32 against Eubacterium spp., 19:227-234 Accuprobe tests Agar dilution methods against Fusobacterium spp., 19:227-234 for mycobacteria, 18:137-139 in anaerobe susceptibility testing, 18:25- against Gram-negative anaerobic rods, for Staphylococcus aureus, 19:5-8 30 18:25-30 Acinetobacter calcoaceticus in bacterial vaginosis and peritonitis, 20: against Haemophilus influenzae, 18:34 amoxicillin—clavulanate against, 18:185 213-220 against Klebsiella oxytoca, 18:35 cefaclor against, 18:185 for Bacteroides fragilis, 20:135-142 against Klebsiella pneumoniae, 18:35 cefepime against, 18:170 for Corynebacterium spp., 19:171-173 against Legionella pneumophila, 18:34 cefixime against, 18:185 for enterococci, 20:113-116 against Moraxella catarrhalis, 18:34-35 ceftazidime against, 18:170 Etest validated against, 19:151-156 against Morganella morganii, 18:35 cefuroxime against, 18:185 inoculum effects on, 19:163—166 against Neisseria gonorrhoeae, 18:35 ciprofloxacin against, 18:185 for Legionella spp., 19:175-178 against Peptostreptococcus spp., 19:227- FK-037 against, 18:170 for Neisseria gonorrhoeae, 18:175 234 fleroxacin against, 18:185 for Mycobacterium avium-intracellulare, 19: against Porphyomonas spp., 19:227-234 lomefloxacin against, 18:185 179-181 against Prevotella spp., 19:227-234 ofloxacin against, 18:185 for Mycobacterium tuberculosis, 19:179-181 against Proteus mirabilis, 18:35 trimethoprim-sulfamethoxazole against, for Pseudomonas aeruginosa, 19:39-46 against Staphylococcus aureus, 18:33 18:185 Agar screen plate method, for methicillin- against Staphylococcus epidermidis, 18:33 Acinetobacter spp. resistant Staphylococcus aureus, 18: against Staphylococcus saprophyticus, 18: amikacin against, 19:151-156 121-124 33-34 cefepime against, 18:170, 19:33-38 AIDS. See Acquired immunodeficiency syn- against Streptococcus agalactiae, 18:34 cefotaxime against, 18:61-68 drome against Streptococcus pneumoniae, 18:34 ceftazidime against, 18:170, 19:151-156 AMS. See Antibiotic Medium 3 against Streptococcus pyogenes, 18:34 ciprofloxacin against, 18:50-56, 18:61-68, Amikacin against Veillonella parvula, 19:227-234 19:151-156 against Acinetobacter spp., 19:151-156 Amoxicillin—clavulanic acid DU-6859a against, 18:125 against Citrobacter freundii, 19:151-156 against Escherichia coli, 18:263-265 FK-037 against, 18:170, 20:27-32 against Enterobacter cloacae, 19:151-156 against Gram-negative bacilli, 18:181—189 fluoroquinolones against, 18:181 against Enterococcus faecalis, 19:151—-156 against Nocardia spp., 19:101-110 gentamicin against, 19:151-156 against Escherichia coli, 19:151-156 Amoxicillin-probenecid, against Neisseria imipenem against, 19:151—156 against Gram-negative bacilli, 20:175-179 gonorrhoeae, 19:121-127 in Lebanese antimicrobial susceptibility against Klebsiella spp., 19:151-156 Amphotericin, against Sporothrix schenkii, study, 20:151-158 against Mycobacterium chelonae, 19:183- 18:111-115 ofloxacin against, 18:50—56 186 Amphotericin B Pasco Gram-negative nonfermenter sys- against Mycobacterium fortuitum, 19:183- against Candida lusitaniae, 20:127-133 tem for, 19:61-63 186 against Candida spp., 18:89-94, 19:75-80, piperacillin against, 19:151-156 against Mycobacterium genavense, 18:10 20:33-40 piperacillin-tazobactam against, 19:151- against Nocardia spp., 19:101-110 against Torulopsis glabrata, 19:75-80 156 against Proteus spp., 19:151—156 against yeasts, 19:9-13 Ro 23-9424 against, 18:61-68 against Pseudomonas aeruginosa, 19:151- Ampicillin Ro 25-0534 against, 18:61-68 156 against Corynebacterium spp., 19:171-173 ticarcillin—-clavulanic acid against, 19:151- against Serratia marcescens, 19:151—-156 against Enterobacteriaceae, 20:143-149 156 against staphylococci, 20:175-179 against enterococci, 19:57—60, 20:61-67 Acquired immunodeficiency syndrome against Staphylococcus aureus, 19:151-156, against Enterococcus faecium, 18:105—109, (AIDS) 20:175-179 20:41-43 Mycobacterium genavense in, 18:7-12 against Streptococcus pneumoniae, 20:175- against Enterococcus spp., 20:143-149 sporotrichosis in, 18:111-115 179 against Gram-negative anaerobic rods, Acridine orange, for detecting false-posi- Aminoglycosides 18:25-30 tive Bactec blood culture bottles, 20: against enterococci, 20:61-67 against Haemophilus influenzae, 18:41-47, 121-125 against Enterococcus faecium, 20:41-43 20:143-149 Acridinium-ester-labeled DNA probes, for mycobacteria, 18:137—139 false resistance to, 18:133-135 lactoferrin interaction with Salmonella Actinobacillus ureae against Pseudomonas stutzeri, 19:51—-56 spp. and, 20:69-75 ceftriaxone against, 20:105—107 in US national surveillance study, 19: against Listeria monocytogenes, 20:21-25 penicillin against, 20:105-107 204-215 against Moraxella catarrhalis, 20:143-149 Adenoviruses Aminoglycoside-—ceftriaxone, against Pseu- against Neisseria gonorrhoeae, 19:121—127 in enteric clinical specimens, 18:161—166 domonas aeruginosa, 19:39-46 against Pseudomonas aeruginosa, 20:143— pseudoepidemic of, in neonatal intensive Amoxicillin—clavulanate 149 care unit, 18:157-159 against Bacteroides capillosus, 19:227-—234 against Staphylococcus aureus, 18:41-47 226 Subject Index to Volumes 18, 19, and 20 Ampicillin-sulbactam BacteEc NR 6A and 7A blood culture bot- ampicillin against, 18:25-30 against Bacteroides capillosus, 19:227-234 tles, Gram stain/acridine orange- cefoxitin against, 18:25-30 against Bacteroides fragilis, 18:235-241, 19: negative, 20:121-125 chloramphenicol against, 18:25-30 227-234, 20:213-220 BACTEC radiometric system clindamycin against, 18:25-30 against Clostridium spp., 19:227-234, 20: for Mycobacterium avium-intracellulare, 19: piperacillin against, 18:25-30 213-220 179-181 piperacillin—-tazobactam against, 18:25-30 against Enterobacteriaceae, 20:143-149 for Mycobacterium genavense, 18:7—12 ticarcillin against, 18:25-30 against Enterococcus spp., 20:143-149 for Mycobacterium tuberculosis, 19:179-181 ticarcillin-clavulanate against, 18:25-30 against Eubacterium spp., 19:227-234 Bacteremia Bartels Prima enzyme immunoassay, for against Fusobacterium spp., 19:227-234, Enterococcus faecium in, 20:41-43 Toxoplasma-specific IgG, 19:19-24 20:213-220 Oerskovia xanthineolytica in, 18:259-261 Bartels Prima System Toxin enzyme immu- against Gram-negative bacilli, 19:111-120 Bacteroides capillosus noassay, for Clostridium difficile, 20: against Gram-positive cocci, 19:111-120 amoxicillin-clavulanate against, 19:227- 1-5 against Haemophilus influenzae, 20:143-149 234 Bartel’s viral transport medium, virus sur- against Lactobacillus spp., 20:213-220 ampicillin-sulbactam against, 19:227-234 vival in, 19:137-142 against Mobiluncus spp., 20:213-220 ceftriaxone against, 19:227-234 Bauer-Kirby disk diffusion against Moraxella catarrhalis, 20:143-149 ceftriaxone-tazobactam against, 19:227- for Enterobacter spp., 18:251-258 against Peptostreptococcus spp., 19:227- 234 for Klebsiella spp., 18:251-258 234, 20:213-220 metronidazole against, 19:227-234 for Pseudomonas aeruginosa, 18:251-258 against Porphyomonas spp., 19:227-234 piperacillin-tazobactam against, 19:227- Becton Dickinson radiometric system, in against Prevotella bivia/disiens, 20:213-220 234 isolation of Mycobacterium genavense, against Prevotella spp., 19:227-234 tazobactam against, 19:227-234 18:7-12 against Pseudomonas aeruginosa, 20:143- ticarcillin—-clavulanate against, 19:227-234 8-Lactamases 149 Bacteroides fragilis group extended spectrum, 20:203-208 against Veillonella parvula, 19:227-234 amoxicillin-clavulanate against, 18:25- in US national surveillance study, 19: Amplicor test, for Chlamydia trachomatis, 20: 30, 18:235-241, 19:227-234 204-215 195-201 ampicillin against, 18:25-30 B-Lactams Antibiotic Medium 3 (AM3), Candida spp. ampicillin-sulbactam against, 18:235- against Enterococcus faecalis, 18:31-39 in, 18:89-94 241, 19:227-234, 20:213-220 against Escherichia coli, 18:31-39 Antibodies cefmetazole against, 18:235-241 against Gram-negative bacilli, 19:111-120 to Chlamydia pneumoniae, 18:229-233 cefoperazone against, 18:235-241 against Gram-positive cocci, 19:111-120 to Clostridium difficile, 18:205-209 cefoperazone-sulbactam against, 18:235- against Haemophilus influenzae, 18:31-39 to cytomegalovirus, 20:109-112 241 against Klebsiella oxytoca, 18:31-39 to Strongyloides stercoralis, 18:19-23 cefotaxime against, 18:61-68, 18:235-241, against Klebsiella pneumoniae, 18:31-39 to varicella—zoster virus, 20:117 20:135-142, 20:213-220 against Legionella pneumophila, 18:31-39 API 20GP system, for staphylococci, 18: cefotetan against, 18:235-241 against Moraxella catarrhalis, 18:31-39 151-155 cefoxitin against, 18:25-30, 18:235-241, against Neisseria gonorrhoeae, 18:31-39 API Staph-Trac system, for staphylococci, 20:135-142 against Proteus mirabilis, 18:31-39 18:151-155 ceftizoxime against, 18:235-241, 20:135- against Staphylococcus aureus, 18:31-39 Artifactual chemoluminescence, in Accu- 142 against Staphylococcus epidermidis, 18:31- probe tests, 18:137-139 ceftriaxone against, 18:235-241, 19:227- 39 Ascitic fluid, in spontaneous bacterial peri- 234, 20:135-142 against Staphylococcus saprophyticus, 18: tonitis, 19:14 ceftriaxone-tazobactam against, 19:227— 31-39 Aspergillus peritonitis, in continuous ambu- 234 against Streptococcus group A, 18:31-39 latory peritoneal dialysis, 20:99-103 chloramphenicol against, 18:25-30 against Streptococcus group B, 18:31-39 Azithromycin, against Haemophilus influen- ciprofloxacin against, 18:61-68, 19:129- against Streptococcus milleri group, 19:70- zae, 18:243-249 133, 19:235-243 73 Aztreonam clindamycin against, 18:25-30, 19:129- against Streptococcus pneumoniae, 18:31-39 against Enterobacter spp., 18:251-258 133, 20:213-220 Biapenem against Gram-negative bacilli, 19:111-120 CP-99,219 against, 19:235-243 against Enterococcus faecalis, 19:65-68 against Gram-positive cocci, 19:111-120 fleroxacin against, 19:129-133 against Klebsiella spp., 18:251-258 grepafloxicin against, 19:129-133 against Pseudomonas aeruginosa, 19:65—-68 against Pseudomonas aeruginosa, 18:251- imipenem against, 18:235-241, 19:129- against Staphylococcus aureus, 19:65-68 258 133, 20:213-220 Bioassay quantitation, of ramoplanin, 18: metronidazole against, 19:129-133, 19: 117-119 Bacillus spp. 227-234, 20:135-142 BioMerieux Vitek enzyme-linked fluores- cefepime against, 18:167-173 piperacillin against, 18:25-30, 20:135-142 cent assay, for Toxoplasma-specific ceftazidime against, 18:167-173 piperacillin-tazobactam against, 18:25- IgG, 19:19-24 FK-037 against, 18:167-173 30, 18:235-241, 19:227-234 Blocking assay, for chlamydial antigen, 18: Bacitracin, against Enterococcus faecium, 18: Ro 23-9424 against, 18:61-68 101-104 105-109 Ro 25-0534 against, 18:61-68 Blood cultures BactTEc 12B media, for mycobacteria, 18: sparfloxacin against, 19:235-243 cytomegalovirus in, 19:15-18 137-139 tazobactam against, 19:227-234 enterococci in, 20:61-67 Bactec 13A blood cultures, for mycobacte- ticarcillin against, 18:25-30 Enterococcus faecalis in, 19:197-202 ria, 18:137-139 ticarcillin-clavulanate against, 18:25-30, Pseudomonas stutzeri in, 19:51-56 BacTEC nonradiometric culture system, for 19:227-234 Salmonella typhi in, 18:75-78 spontaneous bacterial peritonitis, 19: Bacteroides spp. staphylococci in, 18:1-5, 18:151-155 14 amoxicillin—-clavulanate against, 18:25-30 Staphylococcus aureus in, 19:5-8 Subject Index to Volumes 18, 19, and 20 Streptococcus pneumoniae in, 19:157-161, 5-fluorocytosine against, 19:10, 19:218- against Acinetobacter spp., 18:170 20:187-193 219 against Aeromonas hydrophila, 18:170 Brain vessels, Sporothrix schenkii in, 18:111- CAT. See Ceftamet pivoxil against Bacillus spp., 18:167-173 115 Catheters against ceftazidime-resistant isolates, 19: Bronchoalveolar lavage smears, Pneumocys- Aspergillus in, 20:99-103 33-38 tis carinii in, 18:197-199 Candida spp. in, 20:40 against Citrobacter diversus, 18:168 Bronchoscopic diagnosis, of Coccidioides im- Oerskovia xanthineolytica in, 18:259-261 against Citrobacter freundii, 18:168, 20:49- mitis, 18:83-87 Cefaclor 55 Broth microdilution method against Citrobacter diversus, 18:130 against Corynebacterium jeikeium, 20:49-55 for Bacteroides fragilis, 18:235-241, 20:135- against Citrobacter freundti, 18:130 against Enterobacter aerogenes, 18:168 142 against Corynebacterium spp., 18:130 against Enterobacter cloacae, 18:168, 20:49- CP-99219 in, 20:167-170 against Enterobacter spp., 18:129 55 inoculum density and, 18:191-195 against Enterococcus faecalis, 18:34, 18:130 against Enterobacteriaceae, 18:167-173 for staphylococci, 19:167—170 against Escherichia coli, 18:35, 18:130 against Enterobacter sakazakii, 18:168 Buffered charcoal—yeast extract against Gram-negative bacilli, 18:129, 18: against Enterobacter spp., 18:167-173 for Legionella pneumophila, 20:159-162 181-189 against enterococci, 18:167-173, 20:49-55 for Legionella spp., 19:175-178 against Haemophilus influenzae, 18:34, 18: against Enterococcus avium, 18:171 Buffered yeast extract agar, for Legionella 41-47, 18:129-132 against Enterococcus faecalis, 18:171 spp., 19:175-178 against Haemophilus parainfluenzae, 18:130 against Enterococcus faecium, 18:171 Buffy-coat specimens, cytomegalovirus in, against Klebsiella oxytoca, 18:35, 18:130 against Enterococcus spp., 18:171 20:13-19 against Klebsiella pneumoniae, 18:35, 18: against Escherichia coli, 18:168 Buoyant density centrifugation, of hyal- 130 against Flavobacterium spp., 18:170 uronic acid capsules on group A against Legionella pneumophila, 18:34 against Flavobacterium spp., 18:167-173 streptococci, 20:77—-80 against Moraxella catarrhalis, 18:34-35, 18: against Gram-negative bacilli, 18:167-173 Bush group I B-lactamase-producing 129-132 against Gram-positive cocci, 18:167-173 strains, cefepime against, 19:33-38 against Morganella morganii, 18:35 against Haemophilus influenzae, 20:49-55 Bush group II enzymes, cefquinome and, against Neisseria gonorrhoeae, 18:35 against Klebsiella oxytoca, 18:168 20:49-55 against Proteus mirabilis, 18:35, 18:130 against Klebsiella pneumoniae, 18:168 against Serratia marcescens, 18:130 against Moraxella catarrhalis, 20:49-55 Cambridge Bioscience immunoassays, of against Staphylococcus aureus, 18:33, 18: against Morganella morganti, 18:168 adenoviruses, 18:161—166 41-47, 18:130 against Neisseria gonorrhoeae, 20:49-55 Campylobacter spp., DU-6859a against, 20: against Staphylococcus epidermidis, 18:33, against Proteus mirabilis, 18:168 45-47 18:130 against Providencia rettgeri, 18:168 against Staphylococcus haemolyticus, 18:130 against Providencia spp., 18:167-173 Candida albicans amphotericin B against, 19:10 against Staphylococcus hominis, 18:130 against Providencia stuartii, 20:49-55 against Staphylococcus saprophyticus, 18: against Pseudomonas aeruginosa, 18:167- fluconazole against, 19:10, 19:218-219 5-fluorocytosine against, 19:10, 19:218- 33-34, 18:130 173, 20:49-55 219 against Streptococcus agalactiae, 18:34 against Pseudomonas spp., 18:167—173 Candida kruset against Streptococcus imitis, 18:130 against Salmonella spp., 18:168 against Streptococcus pneumoniae, 18:130 against Serratia liquefaciens, 18:167-173 amphotericin B against, 19:10 against Streptococcus pyogenes, 18:34 against Serratia marcescens, 18:169 fluconazole against, 19:10, 19:218-219 against Streptococcus sanguis, 18:130 against Serratia spp., 18:169 5-fluorocytosine against, 19:10, 19:218— against Streptococcus spp., 18:130 against staphylococci, 18:171 219 Cefalexin, lactoferrin interaction with Sal- against Staphylococcus aureus, 18:167-173, Candida lusitaniae monella spp. and, 20:69-75 18:205, 20:49-55 amphotericin B against, 20:127-133 Cefazolin, in US national surveillance against Staphylococcus epidermidis, 18:171 fluconazole against, 19:219, 20:127-133 study, 19:203-215 against Staphylococcus haemolyticus, 18:171 5-fluorocytosine against, 19:219, 20:127- Cefdinir (FK482) against Staphylococcus hominis, 18:171 133 against Enterococcus faecalis, 18:31-39 against Staphylococcus saprophyticus, 18: itraconazole against, 20:127-133 against Escherichia coli, 18:31-39 171 Candida parapsilosis against Haemophilus influenzae, 18:31-39, against streptococci, 18:167—173 amphotericin B against, 19:10 18:41-47 against Streptococcus spp., 20:49-55 fluconazole against, 19:10, 19:218-219 against Klebsiella oxytoca, 18:31-39 against Xanthomonas maltophilia, 18:167- 5-fluorocytosine against, 19:10, 19:218— against Klebsiella pneumoniae, 18:31-39 173 219 against Legionella pneumophila, 18:31-39 Cefixime Candida spp. against Moraxella catarrhalis, 18:31-39 against Enterococcus faecalis, 18:34 amphotericin B against, 18:89-94, 19:75- against Neisseria gonorrhoeae, 18:31-39 against Escherichia coli, 18:35 80, 20:33—40 against Proteus mirabilis, 18:31-39 against Gram-negative bacilli, 18:181-189 cilofungin against, 18:89-94 against Staphylococcus aureus, 18:31-47 against Haemophilus influenzae, 18:34 D0870 against, 19:75-80 against Staphylococcus epidermidis, 18:31- against Klebsiella oxytoca, 18:35 fluconazole against, 19:75-80, 20:81-91 39 against Klebsiella pneumoniae, 18:35 5-fluorocytosine against, 18:89-94, 19:75- against Staphylococcus saprophyticus, 18: against Legionella pneumophila, 18:34 80 31-39 against Moraxella catarrhalis, 18:34-35 itraconazole against, 19:75-80 against Streptococcus group A, 18:31-39 against Morganella morganit, 18:35 in shunt infection, 20:33-40 against Streptococcus group B, 18:31-39 against Neisseria gonorrhoeae, 18:35 Candida tropicalis against Streptococcus pneumoniae, 18:31-39 against Proteus mirabilis, 18:35 amphotericin B against, 19:10 Cefepime against Staphylococcus aureus, 18:33 fluconazole against, 19:10, 19:218-219 against Acinetobacter calcoaceticus, 18:170 against Staphylococcus epidermidis, 18:33 228 Subject Index to Volumes 18, 19, and 20 against Staphylococcus saprophyticus, 18: against streptococci, 18:61 against Klebsiella oxytoca, 18:130 33-34 against Streptococcus spp., 20:49-55 against Klebsiella pneumoniae, 18:130 against Streptococcus agalactiae, 18:34, 18: against Veillonella parvula, 18:194, 20:135- against Moraxella catarrhalis, 18:129-132 65 142 against Proteus mirabilis, 18:130 against Streptococcus pneumoniae, 18:34, against Xanthomonas maltophilia, 18:61-68 against Serratia marcescens, 18:130 18:65 Cefotetan against Staphylococcus aureus, 18:130 against Streptococcus pyogenes, 18:34, 18:65 against Bacteroides fragilis, 18:193, 18:235- against Staphylococcus epidermidis, 18:130 Cefmetazole, against Bacteroides fragilis, 18: 241 against Staphylococcus haemolyticus, 18:130 235-241 against Bacteroides thetaiotamicron, 18:193 against Staphylococcus hominis, 18:130 Cefoperazone against Clostridium perfringens, 18:193 against Staphylococcus saprophyticus, 18: against Bacteroides fragilis, 18:193, 18:235- against Eubacterium lentum, 18:193 130 241 against Fusobacterium necrophorum, 18:194 against Streptococcus imitis, 18:130 against Bacteroides thetaiotamicron, 18:193 against Fusobacterium nucleatum, 18:194 against Streptococcus pneumoniae, 18:130 against Clostridium perfringens, 18:193 against Gram-negative bacilli, 19:111—120 against Streptococcus sanguis, 18:130 against Enterobacter spp., 18:251-258 against Gram-positive cocci, 19:111—120 against Streptococcus spp., 18:130 against Eubacterium lentum, 18:193 against Peptostreptococcus anaerobius, 18: Cefquinome (HR 111V) against Fusobacterium necrophorum, 18:194 193 against Citrobacter freundii, 20:49-55 against Fusobacterium nucleatum, 18:194 against Veillonella parvula, 18:194 against Corynebacterium jeikeium, 20:49-55 against Klebsiella spp., 18:251-258 Cefoxitin against Enterobacter cloacae, 20:49-55 against Peptostreptococcus anaerobius, 18: against Bacteroides fragilis, 18:193, 18:235- against enterococci, 20:49-55 193 241, 20:135-142 against Haemophilus influenzae, 20:49-55 against Pseudomonas aeruginosa, 18:251- against Bacteroides thetaiotamicron, 18:193 against Moraxella catarrhalis, 20:49-55 258 against Clostridium perfringens, 18:193 against Neisseria gonorrhoeae, 20:49-55 against Veillonella parvula, 18:194 against Eubacterium lentum, 18:193 against Providencia stuartii, 20:49-55 Cefoperazone-sulbactam, against Bacteroi- against Fusobacterium necrophorum, 18:194 against Pseudomonas aeruginosa, 20:49-55 des fragilis, 18:235-241 against Fusobacterium nucleatum, 18:194 against Staphylococcus aureus, 20:49-55 Cefotaxime against Gram-negative bacilli, 18:25-30, against Streptococcus spp., 20:49-55 against Acinetobacter spp., 18:61-68 19:111-120 Ceftamet pivoxil (CAT), against Neisseria against Bacteroides fragilis, 18:61-68, 18: against Gram-positive cocci, 19:111-120 gonorrhoeae, 19:121-127 193, 18:235-241, 20:135-142, 20:213- against Mycobacterium chelonae, 19:183— Ceftazidime 220 186 against Acinetobacter calcoaceticus, 18:170 against Bacteroides thetaiotamicron, 18:193 against Mycobacterium fortuitum, 19:183- against Acinetobacter spp., 18:170, 19:151- against Citrobacter freundii, 20:49-55 186 156 against Clostridium perfringens, 18:193 against Neisseria gonorrhoeae, 18:177-178 against Aeromonas hydrophila, 18:170 against Clostridium spp., 20:213—220 against Prevotella spp., 20:135-142 against Bacillus spp., 18:167-173 against Corynebacterium jeikeium, 20:49-55 against Veillonella parvula, 18:194, 20:135- cefepime and, 19:33-38 against Enterobacter cloacae, 20:49-55 142 against Citrobacter diversus, 18:168 against Enterobacteriaceae, 18:61, 20: Cefpirome against Citrobacter freundii, 18:168, 19: 143-149 against Citrobacter freundii, 20:49-55 151-156, 20:49-55 against enterococci, 18:61-68, 20:49-55 against Corynebacterium jeikeium, 20:49-55 against Corynebacterium jeikeium, 20:49-55 against Enterococcus spp., 20:143-149 against Enterobacter cloacae, 20:49-55 against Enterobacter aerogenes, 18:168 against Eubacterium lentum, 18:193 against enterococci, 20:49-55 against Enterobacter cloacae, 18:168, 19: against Fusobacterium necrophorum, 18:194 against Haemophilus influenzae, 20:49-55 151-156, 20:49-55 against Fusobacterium nucleatum, 18:194 against Moraxella catarrhalis, 20:49-55 against Enterobacteriaceae, 18:167-173 against Fusobacterium spp., 20:213-220 against Neisseria gonorrhoeae, 20:49-55 against Enterobacter sakazakii, 18:168 against Gram-negative bacilli, 18:61, 19: against Providencia stuartii, 20:49-55 against Enterobacter spp., 18:167-173, 18: 111-120 against Pseudomonas aeruginosa, 20:49-55 251-258 against Gram-positive cocci, 19:111—120 against Staphylococcus aureus, 20:49-55 against enterococci, 18:167—173, 20:49-55 against Haemophilus influenzae, 18:61-68, against Streptococcus spp., 20:49-55 against Enterococcus avium, 18:171 20:49-55, 20:143-149 Cefpodoxime against Enterococcus faecalis, 18:171, 19: against Lactobacillus spp., 20:213-220 against Staphylococcus aureus, 18:33 151-156 against Mobiluncus spp., 20:213-—220 against Staphylococcus epidermidis, 18:33 against Enterococcus faecium, 18:171 against Moraxella catarrhalis, 18:61-68, 20: against Staphylococcus saprophyticus, 18: against Enterococcus spp., 18:171 49-55, 20:143-149 33-34 against Escherichia coli, 18:168, 19:151- against Neisseria gonorrhoeae, 20:49-55 Cefpodoxime proxetil 156, 20:203—208 against Nocardia spp., 19:101-110 against Escherichia coli, 18:263-265 against Flavobacterium spp., 18:167-173 against Peptostreptococcus anaerobius, 18: against Haemophilus influenzae, 18:41-47 against Gram-negative bacilli, 18:167-173, 193 against Staphylococcus aureus, 18:41-47 19:111-120, 20:175-179 against Peptostreptococcus spp., 20:213- Cefprozil against Gram-positive cocci, 18:167-173, 220 against Citrobacter diversus, 18:130 19:111-120 against pneumococci, 18:61 against Citrobacter freundii, 18:130 against Haemophilus influenzae, 20:49-55 against Prevotella bivia/disiens, 20:213—220 against Corynebacterium spp., 18:130 against Klebsiella oxytoca, 18:168 against Prevotella spp., 20:135-142 against Enterobacter spp., 18:129 against Klebsiella pneumoniae, 18:168, 20: against Providencia stuartii, 20:49-55 against Enterococcus faecalis, 18:130 203-208 against Pseudomonas aeruginosa, 18:61-68, against Escherichia coli, 18:130 against Klebsiella spp., 18:251-258, 19: 20:49-55, 20:143-149 against Gram-negative bacilli, 18:129 151-156 against staphylococci, 18:61 against Haemophilus influenzae, 18:129-132 against Moraxella catarrhalis, 20:49-55 against Staphylococcus aureus, 20:49-55 against Haemophilus parainfluenzae, 18:130 against Morganella morganii, 18:168 Subject Index to Volumes 18, 19, and 20 against Neisseria gonorrhoeae, 20:49-55 against Haemophilus influenzae, 20:143-149 in US national surveillance study, 19: against Proteus mirabilis, 18:168 against Klebsiella spp., 18:251-258 204-215 against Proteus spp., 19:151-156 against Moraxella catarrhalis, 20:143-149 Cephamins, against Bacteroides fragilis, 18: against Providencia rettgeri, 18:168 against Neisseria gonorrhoeae, 18:175, 177- 235-241 against Providencia spp., 18:167-173 178 Cerebrospinal fluid (CSF) against Providencia stuartit, 20:49-55 against Nocardia spp., 19:101-110 Candida spp. in, 20:33—+0 against Pseudomonas aeruginosa, 18:167- against Pasteurella ureae, 20:105-107 Sporothrix schenkii in, 18:111-115 173, 18:251-258, 19:151-156, 20:49-55 against Peptostreptococcus anaerobius, 18: Streptococcus pneumoniae in, 18:211-214, against Pseudomonas spp., 18:167-173 193 19:157-161 against Salmonella spp., 18:168 against Peptostreptococcus spp., 19:227- Cervical intraepithelial neoplasia (CIN), against Serratia liquefaciens, 18:167—173 234 human papillomavirus in, 18:95-100 against Serratia marcescens, 18:169, 19: against Porphyomonas spp., 19:227-234 Checkerboard assays, of Pseudomonas aeru- 151-156 against Prevotella spp., 19:227-234, 20: ginosa susceptibility, 19:39-46 against Serratia spp., 18:169 135-142 Chemotherapy against staphylococci, 18:171, 18:209, 20: against Pseudomonas aeruginosa, 18:251- antistaphylococcal, 19:25-31 175-179 258, 20:143-149 strongyloidiasis evaluation after, 18:19- against Staphylococcus aureus, 18:167-173, in US national surveillance study, 19: 23 19:151-156, 20:49-55, 20:175-179 204-215 Chlamydia pneumoniae, antibody to, 18:229, against Staphylococcus epidermidis, 18:171 against Veillonella parvula, 18:194, 19:227- 230-233 against Staphylococcus haemolyticus, 18:171 234, 20:135-142 Chlamydia trachomatis against Staphylococcus hominis, 18:171 Ceftriaxone-netilmicin, against Pseudomo- Amplicor test for, 20:195-201 against Staphylococcus saprophyticus, 18: nas aeruginosa, 19:39-46 automated enzyme-linked fluorescent as- 171 Ceftriaxone—tazobactam say for, 18:101-104 against streptococci, 18:167-173 against Bacteroides capillosus, 19:227-234 Chlamidiazyme, with blocking assay, for against Streptococcus pneumoniae, 20:175- against Bacteroides fragilis, 19:227-234 chlamydial antigen, 18:101—104 179 against Clostridium spp., 19:227-234 Chloramphenicol against Streptococcus spp., 20:49-55 against Eubacterium spp., 19:227-234 against Enterococcus faecium, 20:42 in US national surveillance study, 19: against Fusobacterium spp., 19:227-234 against Gram-negative anaerobic rods, 203-215 against Peptostreptococcus spp., 19:227- 18:25-30 against Xanthomonas maltophilia, 18:167- 234 lactoferrin interaction with Salmonella 173 against Porphyomonas spp., 19:227-234 spp. and, 20:69-75 Ceftazidime-netilmicin, against Pseudomo- against Prevotella spp., 19:227-234 against Streptococcus milleri group, 19:70- nas aeruginosa, 19:39-46 against Veillonella parvula, 19:227-234 73 Ceftazidime-tobramycin, against Pseudomo- Ceftriaxone-tobramycin, against Pseudomo- Chocolate—Mueller-Hinton agar, Neisseria nas aeruginosa, 19:39-46 nas aeruginosa, 19:39-46 gonorrhoeae on, 18:175 Ceftizoxime Cefuroxime Chromosomes, in Mycobacterium tuberculo- against Bacteroides fragilis, 18:193, 18:235- against Enterobacteriaceae, 20:143-149 sis, 18:215-218 241, 20:135-142 against Enterococcus spp., 20:143-149 CI-960, against Enterococcus faecium, 20:42 against Bacteroides thetaiotamicron, 18:193 against Escherichia coli, 20:203-208 Cigarette smoking, human papillomavirus against Clostridium perfringens, 18:193 against Gram-negative bacilli, 18:181-189, risk and, 18:95—100 against Eubacterium lentum, 18:193 19:111-120 Cilofungin (LY121019), against Candida against Fusobacterium necrophorum, 18:194 against Gram-positive cocci, 19:111—120 spp., 18:89-94 against Fusobacterium nucleatum, 18:194 CIN. See Cervical intraepithelial neoplasia against Haemophilus influenzae, 20:143-149 against Haemophilus influenzae, 19:65—-68 Ciprofloxacin against Klebsiella pneumoniae, 20:203—208 against Neisseria gonorrhoeae, 19:65-68 against Acinetobacter spp., 18:50-56, 18: lactoferrin interaction with Salmonella against Peptostreptococcus anaerobius, 18: 61-68, 19:151-156 spp. and, 20:69-75 193 against anaerobic bacteria, 19:129-133 against Moraxella catarrhalis, 20:143-149 against Prevotella spp., 20:135—-142 against Bacteroides fragilis, 18:61-68, 19: against Pseudomonas aeruginosa, 20:143— against Veillonella parvula, 18:194, 20:135- 129-133, 19:235-243 149 142 cefepime and, 19:33-38 in US national surveillance study, 19: Ceftriaxone against Citrobacter diversus, 19:235-243 203-215 against Aspergillus ureae, 20:105-107 against Citrobacter freundii, 19:151-156, Cell culture against Bacteroides capillosus, 19:227—234 19:235-243 against Bacteroides fragilis, 18:193, 18:235- chlamydial antigen, 18:101—104 against Corynebacterium spp., 19:171-173 241, 19:227-234, 20:135-142 virus survival in, 19:137-142 in disk diffusion tests, 18:125-127 against Bacteroides thetaiotamicron, 18:193 Cephalexin against Enterobacter aerogenes, 19:235-243 against Clostridium perfringens, 18:193 against Staphylococcus aureus, 18:33 against Enterobacter cloacae, 19:151-156, against Clostridium spp., 19:227-234 against Staphylococcus epidermidis, 18:33 19:235-243 against Enterobacteriaceae, 20:143-149 against Staphylococcus saprophyticus, 18: against Enterobacteriaceae, 18:61, 19: against Enterobacter spp., 18:251-258 33-34 235-243 against Enterococcus spp., 20:143-149 Cephalosporins against Enterobacter spp., 18:251-258 against Eubacterium lentum, 18:193 against Bacteroides fragilis, 18:235-241 against enterococci, 18:61 against Eubacterium spp., 19:227-234 against Gram-negative bacilli, 19:33-38 against Enterococcus faecalis, 19:151-156, against Fusobacterium necrophorum, 18:194 against Haemophilus influenzae, 18:41-47 19:235-243 against Fusobacterium nucleatum, 18:194 against Neisseria gonorrhoeae, 19:121-127 against Enterococcus faecium, 20:42 against Fusobacterium spp., 19:227-234 against Pseudomonas stutzeri, 19:51-56 against Enterococcus spp., 18:50-56 against Gram-negative bacilli, 19:111-120 against staphylococci, 18:31-39, 18:65 against Escherichia coli, 19:151-156, 19: against Gram-positive cocci, 19:111-120 against Staphylococcus aureus, 18:41-47 235-243, 20:45-47 230 Subject Index to Volumes 18, 19, and 20 against Gram-negative bacilli, 18:61, 18: cefixime against, 18:183 ceftriaxone—tazobactam against, 19:227- 181-189, 19:111-120 cefprozil against, 18:130 234 against Gram-positive cocci, 18:50-56, 19: ceftazidime against, 18:168, 19:151-156 clindamycin against, 20:213-220 111-120 cefotaxime against, 20:49-55 imipenem against, 20:213-220 against Haemophilus influenzae, 18:61-68 cefpirome against, 20:49-55 metronidazole against, 19:227—234, 20: against Helicobacter pylori, 19:235-243 cefquinome against, 20:49-55 135-142 against Klebsiella oxytoca, 19:235-243 ceftazidime against, 20:49-55 piperacillin against, 20:135-142 against Klebsiella pneumoniae, 19:235-243 cefuroxime against, 18:183 piperacillin-tazobactam against, 19:227- against Klebsiella spp., 18:251-258, 19: ciprofloxacin against, 18:183, 19:151—156, 234 151-156 19:235—243 tazobactam against, 19:227-234 lactoferrin interaction with Salmonella CP-99,219 against, 19:235-243 ticarcillin—clavulanate against, 19:227-234 spp. and, 20:69-75 FK-037 against, 18:168, 20:27-32 CMH agar, Neisseria gonorrhoeae on, 18:175 against Listeria monocytogenes, 20:21-25 fleroxacin against, 18:183 CMV. See Cytomegalovirus against Moraxella catarrhalis, 18:61-68 gentamicin against, 19:151-156 CMV-Gen test, for cytomegalovirus anti- against Morganella morganti, 19:235-243 imipenem against, 19:151-156 body, 20:109-112 against Mycobacterium avium-intracellu- lomefloxacin against, 18:183, 20:93-98 CMV-Scan test, for cytomegalovirus anti- lare, 19:179-181 ofloxacin against, 18:183 body, 20:109-112 against Mycobacterium chelonae, 19:183— piperacillin against, 19:151-156 CMV-vue antigenemia assay, for CMV de- 186 piperacillin-tazobactam against, 19:151- tection in peripheral blood leuko- against Mycobacterium fortuitum, 19:183- 156 cytes, 19:15-18 186 sparfloxacin against, 19:235-243 Coccidioides immitis, bronchoscopic diagno- against Mycobacterium genavense, 18:10 ticarcillin—clavulanic acid against, 19:151- sis of, 18:83-87 against Nocardia spp., 19:101-110 156 Colistin, Streptococcus group B cultures and, ofloxacin and, 18:49-56 trimethoprim-sulfamethoxazole against, 18:141-144 against pneumococci, 18:61 18:183 Colorimetric microdilution method, for against Proteus spp., 19:151-156 Citrobacter spp., in Lebanese antimicrobial yeasts, 19:9-13 against Pseudomonas aeruginosa, 18:61-68, susceptibility study, 20:151-158 Color Vue enzyme-linked immunosorbent 18:251-258, 19:151-156, 19:235-243 Clal, in ribotyping Pseudomonas cepacia, 20: assay, for Cryptosporidium spp., 19: against Salmonella spp., 20:46 181-186 221-225 against Salmonella typhi, 20:46 Clarithromycin Community-aquired infections against Serratia marcescens, 19:151-156, against Haemophilus influenzae, 18:243-—249 cefaclor against, 18:129 19:235-243 against Mycobacterium genavense, 18:10 cefprozil against, 18:129 against Shigella spp., 20:46 Clindamycin pneumonia, 18:259-261 against staphylococci, 18:50-56, 18:61, 19: against anaerobic bacteria, 19:129-133 Complement fixation test, for Chlamydia 143-147, 19:235-243 against Bacteroides fragilis, 18:235-241, 19: pneumoniae, 18:229-233 against Staphylococcus aureus, 19:143-147, 129-133, 20:213-220 Corynebacterium jeikeium 19:151-156 against Clostridium spp., 20:213-220 ampicillin against, 19:171-173 against streptococci, 18:61 against Fusobacterium spp., 20:213-220 cefepime against, 20:49-55 against Streptococcus pneumoniae, 19:235— against Gram-negative anaerobic rods, cefotaxime against, 20:49-55 243 18:25-30 cefpirome against, 20:49-55 against Streptococcus pyogenes, 19:235-243 against Lactobacillus spp., 20:213-220 cefquinome against, 20:49-55 in US national surveillance study, 19: against Legionella spp., 19:175-178 ceftazidime against, 20:49-55 203-215 against Mobiluncus spp., 20:213-220 ciprofloxacin against, 19:171-173 against Xanthomonas maltophilia, 18:61-68 against Peptostreptococcus spp., 20:213- doxycycline against, 19:171-173 Citrate-anticoagulated whole blood, Strep- 220 erythromycin against, 19:171-173 tococcus pneumoniae and, 20:187-193 against Prevotella bivia/disiens, 20:213-220 gentamicin against, 19:171-173 Citrobacter diversus against Streptococcus milleri group, 19:70- vancomycin against, 19:171—-173 amoxicillin-clavulanate against, 18:183 73 Corynebacterium spp. cefaclor against, 18:130, 18:163 Clofazimine, against Mycobacterium gena- cefaclor against, 18:130 cefepime against, 18:168 vense, 18:10 cefprozil against, 18:130 cefixime against, 18:183 Clostridium difficile ciprofloxacin against, 19:171-173 cefprozil against, 18:130 Bartels Prima System Toxin enzyme im- doxycycline against, 19:171-173 ceftazidime against, 18:168 munoassay for, 20:1—5 erythromycin against, 19:171-173 cefuroxime against, 18:183 FK-307 against, 20:27-—32 gentamicin against, 19:171-173 ciprofloxacin against, 18:183, 19:235-243 TechLab Tox-A enzyme immunoassay vancomycin against, 19:171-173 CP-99,219 against, 19:235-243 for, 20:1-5 Corynebacterium urealyticum FK-037 against, 18:168 toxins A and B, IgG against, 18:205-209 ampicillin against, 19:171-173 fleroxacin against, 18:183 Clostridium spp. ciprofloxacin against, 19:171-173 lomefloxacin against, 18:183 amoxicillin—clavulanate against, 19:227- doxycycline against, 19:171-173 ofloxacin against, 18:183 234 erythromycin against, 19:171-173 sparfloxacin against, 19:235-243 ampicillin-sulbactam against, 19:227- gentamicin against, 19:171-173 trimethoprim-sulfamethoxazole against, 234, 20:213-220 vancomycin against, 19:171—173 18:183 cefotaxime against, 20:135-142, 20:213- CP-99,219 Citrobacter freundii 220 against Bacteroides fragilis, 19:235-243 amikacin against, 19:151-156 cefoxitin against, 20:135-142 broth microdilution testing for, 20:167- amoxicillin—clavulanate against, 18:183 ceftizoxime against, 20:135-142 170 cefaclor against, 18:130, 18:183 ceftriaxone against, 19:227-234, 20:135- against Citrobacter diversus, 19:235-243 cefepime against, 18:168, 19:35, 20:49-55 142 against Citrobacter freundii, 19:235-243

See more

The list of books you might like

Most books are stored in the elastic cloud where traffic is expensive. For this reason, we have a limit on daily download.